Director Ralph Elias Green of Vivos Therapeutics, Inc. filed a Form 4 on October 26, 2026, disclosing a grant of 12,000 stock options with an exercise price of $0.18 per share, dated September 14, 2026.

Key Highlights

  • Option grant: Ralph Elias Green received 12,000 stock options on September 14, 2026, with an exercise price of $0.18 per share.
  • Vesting schedule: One-half vested immediately on the grant date, one-fourth will vest on September 30, 2026, and one-fourth will vest on December 31, 2026, according to the filing.
  • Option term: The options are exercisable for a period of 10 years from the grant date, expiring September 14, 2036.
  • Price of derivative security: The filing reports the price of the derivative security as $0.
  • Post-transaction holdings: Following the grant, Green beneficially owns 17,200 stock options directly.
  • Expired options: According to the filing, 667 options expired unexercised on June 19, 2025, and 1,200 options expired unexercised on August 5, 2026.

Vivos Therapeutics Director Green's September 2026 Option Grant Details

According to the Form 4 filed with the SEC on October 26, 2026, Ralph Elias Green, a director of Vivos Therapeutics, Inc. (NASDAQ:VVOS), received a grant of 12,000 stock options on September 14, 2026. The exercise price of the options is reported as $0.18, and the price of the derivative security is listed as $0. The options are classified as "Stock Options (Right to Buy)" for shares of common stock.

The filing describes a three-tranche vesting structure. One-half of the 12,000 options vested immediately on the grant date of September 14, 2026. The remaining shares are scheduled to vest in equal portions: one-fourth on September 30, 2026, and one-fourth on December 31, 2026. All options carry a 10-year exercise window, with an expiration date of September 14, 2036, as disclosed in the filing.

The filing also notes that prior option expirations reduced Green's holdings before this grant. Specifically, 667 options expired unexercised on June 19, 2025, and 1,200 options expired unexercised on August 5, 2026. Following the reported transaction, Green's total beneficial ownership of stock options stands at 17,200, held directly. The Form 4 was signed by Bradford K. Amman as attorney-in-fact for Ralph Elias Green and filed on October 26, 2026.

What Was Disclosed

Vivos Therapeutics director Ralph Elias Green disclosed the acquisition of 12,000 stock options at $0.18 per share on September 14, 2026, with a split vesting schedule and a 10-year term, resulting in total direct beneficial ownership of 17,200 options.